🇺🇸 FDA
Pipeline program

A-101 Solution

A-101-SEBK-302

Phase 3 small_molecule completed

Quick answer

A-101 Solution for Seborrheic Keratosis is a Phase 3 program (small_molecule) at Aclaris Therapeutics with 3 ClinicalTrials.gov record(s).

Program details

Company
Aclaris Therapeutics
Indication
Seborrheic Keratosis
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials